Procoagulant peptides, their derivatives and their application

FIELD: medicine.

SUBSTANCE: group of inventions includes a hemostatic material comprising a peptide having the sequence of SEQ ID NO: 1 or its sequence of amino acid analogs and a framework where the said framework is a natural gelatin polymer, wherein the gelatin comprises an absorbable hemostatic powder matrix, a sponge matrix, a pasty matrix , a gel matrix or combinations thereof, and the said gelatin is cross-linked and has the form of particles with a liquid carrier, as well as a material for tissue healing anal and a method for hemostatic treatment or tissue healing at the wound site, comprising formation of a hemostatic material or tissue healing material of a similar composition and application of a hemostatic material or tissue healing material to the wound site.

EFFECT: expanded arsenal of technical means of hemostatic purpose, which can successfully work in heparinized blood.

33 cl, 8 dwg, 1 tbl, 10 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a medical absorbable haemostatic and wound healing material for osteal wounds and a method for producing it. The absorbable haemostatic material for osteal wounds contains 40-95% of a primary material and 5-60% of an auxiliary on the basis of weight percentage, wherein the primary material contains an oligosaccharide, a polysaccharide or a mixture of the oligosaccharide and polysaccharide, while the auxiliary contains (1) one or more polyatomic alcohols, (2) one or more emulsifiers. The method for producing the absorbable haemostatic and wound healing material for osteal wounds consists of the following stages involving mixing the primary material and auxiliary in the pre-set amounts by chemical mixture and preparation of the mixture at the stage of latex, and cooling to form a solid piece, packaging and sterilising.

EFFECT: material is degradable in the body and promotes osteal wound healing.

7 cl, 4 tbl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injection is added to the lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. At that the dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective the prevention of bleeding caused by the use of streptokinase, prior to surgical interferences.

1 ex, 2 dwg

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.

EFFECT: group of inventions relates to improvement of octreotide bioavailability.

100 cl, 39 ex, 10 dwg, 45 tbl

FIELD: medicine.

SUBSTANCE: medication based on tripeptide Ac-Ala-Phe-Lys-Pip·AcOH or its pharmaceutically acceptable salts is applied. The claimed medication can be made in the form of a solution, gel, plate or sponge.

EFFECT: application of the said medication makes it possible to considerably reduce the volume of haemorrhage and reduce the time of bleeding stopping due to high anti-plasmin activity of the tripeptide Ac-Ala-Phe-Lys-Pip·AcOH with the absence of side effects.

2 cl, 8 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: wound canal is packed with a preparation of recovered oxygenated cellulose. Thereafter in an entrance wound, the preparation is exposed to 2 cycles of cryotherapy with liquid nitrogen at a temperature of minus 196°C for 1-2 minutes until an ice crust is formed on the wound surface.

EFFECT: method provides excluding the possibility of bleeding and bile flowing from an inner surface of stab wounds, reducing a risk of recurrent bleedings, formation of liver haematomas postoperatively.

3 dwg, 2 tbl, 2 ex

Haemostatic agent // 2545991

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.

EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.

1 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula

.

The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R1, R2, R3 andR4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2.

EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility.

19 cl, 1 tbl, 25 ex

FIELD: biotechnology.

SUBSTANCE: bispecific antibody is proposed, that binds to both the blood coagulation factor IX/activated blood coagulation factor IX and with the blood coagulation factor X, and functionally replaces the function of blood coagulation factor VIII. The nucleic acid is considered, encoding the antibody of the invention, a vector, a cell and a method of producing the antibody, and also a pharmaceutical composition and a kit for use in the method of preventing and/or treating bleeding or diseases associated with or caused by bleeding.

EFFECT: invention may find further application in the treatment of diseases associated with impaired blood clotting.

16 cl, 2 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: claimed is bispecific antibody, which is bound with both blood coagulation factor IX/activated blood coagulation factor IX and with blood coagulation factor X and functionally replaced function of blood coagulation factor VIII. Described are nucleic acid, coding antibody by invention, vector, cell and method of obtaining antibody, as well as pharmaceutical composition and set for application in method of prevention and/or treatment of bleeding or diseases, associated with or induced by bleeding.

EFFECT: invention can be applied in therapy of diseases, associated with blood coagulation disorders.

16 cl, 2 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a haemostatic device comprising a carrier material, a surface of which is coated with a printed pharmaceutical composition containing thrombin. What is described is a method for making the haemostatic device comprising the carrier material, the surface of which is coated with the printed pharmaceutical composition. What is described is using the haemostatic device for fastening haemostasis and/or wound healing. The invention also refers to a kit comprising the carrier coated with the pharmaceutical composition and a container with a detachable lid.

EFFECT: printing method enables distributing the composition more accurately on the surface of the carrier material.

32 cl, 7 dwg, 5 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: what is described is a coating in the form of a film which contains the following ingredients, wt %: low-molecular edible chitosan 5.3-5.7, glycerol 2.2-2.8, ceruloplasmin 0.06-0.08, L-asparaginic acid 0.04-0.06, a solvent with pH 5-7 - the rest. What is described is a method for preparing the coating consisting in the fact that a chitosan weigh is diluted in the solvent at 1000 mg of the weigh to 15 ml of the solvent, mixed and placed in a thermostat at a temperature of 37-42°C for 1-2 hours. The mixture is added with ceruloplasmin diluted in the solvent at 1:10 to form a homogenous hydrogel. L-asparaginic acid is diluted in the solvent pre-heated to 37-40°C and added to the mixture to provide pH of the mixture 5-7. A plasticising agent in the form of glycerol is added in the amount of 2.2-2.8% of total volume of the prepared biomass The prepared biomass is placed into containers to form a uniform layer of the coating 3-5 mm high and to form a film by drying the biomass for 18-24 hours in the thermostat at a temperature of 37-40°C.

EFFECT: wound coating provides the highest clinical effect.

6 cl, 6 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. What is described is a haemostatic composition containing a biologically absorbable material and hyaluronic acid or a derivative thereof. There are described methods for preparing the given compositions, and there are described the applications of the given compositions. Particularly, the method for preparing the above haemostatic composition involves the dry heat treatment at temperature 110 to 200°C.

EFFECT: compositions exhibit the enhanced haemostatic properties.

68 cl, 1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a surgical barrier which includes a wound-facing polymeric coating comprising an enteric polymer, and at least one flexible substrate wherein at least one mentioned flexible substrate having at least one exterior surface with said polymeric coating is applied on at least one mentioned flexible substrate so that substantially cover at least one exterior surface thereof. There are also described a method for inhibiting the formation of adhesions in a patient who has undergone a surgical procedure, and a method for repairing a gastric or duodenal perforation.

EFFECT: reduced probability or prevention of the formation of adhesions associated with the surgical intervention.

27 cl, 4 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely traumatology and surgery, and may be used for bleeding control. That is ensured by the use of a composition, as well as an adhesive material containing gelatin and transglutaminase wherein their relation is sufficient for bleeding control in a wound, and wherein said gelatin is not exposed to irreversible gel-formation and forms a solution with transglutaminase at temperature below natural one of a gel-sol junction of standard animal gelatin prepared from an animal source or representing recombinant gelatin or their combination.

EFFECT: use of the given inventions enables reducing time of bleeding control in the wound.

22 cl, 15 dwg, 12 tbl, 15 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Described is method of obtaining disposable atraumatic application, which includes oxidation of medical gauze with obtaining dialdehidecellulose, further immobilisation of medications on it, oxidation being carried out to 6.0+0.33% degree, after that, obtained mixture is grinded until microfibrous form, modified by medicinal components, is obtained, mixed with powder of gel-forming reagent, mixture is intensively mixed with water, then, solution is poured into forms, dried and obtained gel plates are connected with paper layers, made from wood cellulose, by sewing method.

EFFECT: application ensures accelerated purification of wounds from purulent-necrotic masses and reduction of wound-healing terms.

2 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is disclosed is a method for making a bandage containing at least one protein, providing stages of coating the bandage with at least one protein with using common means; and additional pressurisation of the bandage containing the protein at approximately 2500 to approximately 39500 pounds per square inch for a period of time from approximately 2 to approximately 6 seconds.

EFFECT: bandage shows improved haemostatic properties, tissue closure and adhesion properties.

10 cl, 1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Described is patch for application in surgery, produced by method, which includes stages of selection of animals tissue, which contains substrate, diametrical linking and fixation of substrate, minimisation of substrate agents activity, substrate tanning and binding of active layer to substrate.

EFFECT: biological patch for surgery does not induce immune rejection and has good biological compatibility.

17 cl, 1 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine. Described is biological wound covering, produced by method, which includes stages of selection of animal tissue, which contains substrate, of diametrical linking and fixation of substrate, minimisation of substrate agents activity and binding of active layer to substrate.

EFFECT: biological wound covering has good biological compatibility, long-term elasticity, is permeable for gases, but impermeable for bacteria.

20 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Described is method of manufacturing biologically absorbable bandage, which includes envelope and biologically absorbable microspheres, in form of tourniquet. Additionally bandage envelope contains pores, formed by pore-forming system, which can be activated by external way relative to wound, or form in situ within wound surface. Bandage shape makes it possible to place the bandage on wound surface in such a way that it fills wound by shape and size. Described are bandages in form of tourniquet and their application in combination with treatment by reduced pressure is shown.

EFFECT: bandage in form of tourniquet is easy adapted to size and shape of any wound surface.

25 cl, 11 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Described are: fibrin matrix, method of its obtaining and method of processing or prevention of defect on wet tissue of object requiring processing. Described is application for hermetic sealing of defect in mucous membrane or other wet tissue.

EFFECT: fibrin matrix is efficient for sealing tissue leakages.

35 cl, 3 dwg, 1 tbl, 3 ex

Up!